• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

aXichem AB: aXichem obtains order from Actives & Co for aXivite, to be used in product development project for the French market

aXichem
Read the release

aXichem AB (publ), that develops and markets natural analogue industrial compounds, has received the first order for product development from its French distribution partner Actives & Co. aXichem signed a marketing, sales and distribution agreement with Actives & Co, a high quality ingredient provider, at the end of March this year, and the initial order of aXivite will be used in a product development project aiming at finding the formula for a new weight management product.  

- It is very encouraging that we see this activity in the French market. Initially it is a limited order of 15 kilogram of aXivite, but the value lies in the potential and the fact that there now is ongoing product development based on aXichem's capsaicin analogue product, aXivite. Weight control and weight management is a growing segment in France, as in several other markets, and I'm pleased that we have as competitive product to offer, says Lucas Altepost, Vice President at aXichem. 

The French market for food supplements is the third largest market in Europe, behind Italy and Germany, at 610 million Euro in 2013, (FederSalus, 2014). Some sources have estimated the market to be even bigger. The Syndicat National de Compléments Alimentaires (Synadiet) estimates the French market to be much larger at 1.48 billion Euro in 2014, having increased by 6.4 percent since 2013. According to Synadiet, the most popular categories in 2014 were tonics, stress and sedatives, digestion and weight control supplements.

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.